ArticleEuropean journal of medical research2025
Proteomics identifies complement protein signatures in patients with primary biliary cholangitis.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative multi-omics analysis identifies stellate cell-derived complement component 7 as a predictor of fibrosis and liver-related events in MASLD.JHEP reports : innovation in hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease lacking reliable biomarkers for diagnosis or prognosis. To identify plasma complement biomarkers that improve diagnosis and prognosis of PBC. We analyzed large-scale proteomic data from the UK Biobank, concentrating on complement components linked to PBC. A total of 44 PBC patients, including 13 baseline cases and 31 incident cases, were evaluated alongside matched controls based on demographic factors. Proteomic analysis revealed significantly elevated levels of complement proteins, including complement receptor 1 (CR1), complement component 1q subcomponent A chain (C1QA), complement component 1q subcomponent-like 2 (C1QL2), complement component 7 (C7), and component 9 (C9) in PBC patients (P < 0.05). Among these, C1QA, C1QL2, C7, and CR1 demonstrated strong diagnostic potential. Elevated levels of CR1, complement receptor 1 (CR2), C1QA, C1QL2, and C7 were linked to increased risk of PBC onset (P < 0.05). Further analysis revealed that CR1, CR2, C1q and tumor necrosis factor-related protein 1 (C1QTNF1), C1q and tumor necrosis factor-related protein 5 (C1QTNF5), and C7 were associated with more severe liver outcomes (P < 0.05), while lower levels of complement component 5 (C5) and complement C1r subcomponent-like protein (C1RL) correlated with worse outcomes (P = 0.002). Notably, CR1 had the highest predictive accuracy for adverse outcomes (AUC = 81.85), outperforming traditional liver fibrosis markers such as the Fibrosis-4 (FIB-4) index (AUC = 76.33). Complement components, particularly CR1, may serve as valuable biomarkers for diagnosing PBC and predicting its severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.